Comparison of Fexuprazan and Esomeprazole for the Control of Nocturnal Gastroesophageal Reflux Symptoms: A Randomized, Crossover Study
Journal of Neurogastroenterology and Motility · 30.01.2026 · 32 (1) · 52-60
DOI: 10.5056/jnm25119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurogastroenterology and Motility, online erschienen am 25.08.2025. Verfasst von Dong Jun Oh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Gyeonggi-do, Korea. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dongguk University, Daewoong Pharmaceutical Company.
Abstract (Originalsprache)
Background/Aims: : Nocturnal acid reflux disrupts sleep and impairs quality of life. Proton pump inhibitors provide insufficient suppression of nocturnal acid secretion, whereas fexuprazan offers prolonged acid suppression. We compared the efficacy of fexuprazan and esomeprazole in controlling nocturnal reflux. Methods: : In a randomized and crossover study, patients received fexuprazan or esomeprazole daily for 4 weeks, followed by a washout and crossover to the alternate medication for another 4 weeks, with a final washout completing the sequence. Severity (scores 0-10), frequency, sleep disturbance, and medication preferences were evaluated. Results: : Thirty-nine patients were enrolled and randomized to receive either fexuprazan (n = 20) or esomeprazole (n = 19) first. After the first treatment, fexuprazan reduced severity from 7.5 ± 1.7 to 1.4 ± 1.7 (81.3% decrease), versus 7.8 ± 1.5 to 2.8 ± 1.9 (64.1% decrease) with esomeprazole (P = 0.012). In patients with severe symptoms (scores ≥ 7), fexuprazan led to significantly greater improvement than esomeprazole (P = 0.008). Following the first washout, the second crossover treatment resulted in greater improvement in symptom severity with fexuprazan (P = 0.001). During the second washout, nocturnal symptoms severity and frequencies were better controlled with fexuprazan than with esomeprazole (P = 0.005 and 0.019). Patients who switched from esomeprazole to fexuprazan preferred fexuprazan (P = 0.018). Conclusions: : Fexuprazan was more effective than esomeprazole in controlling nocturnal reflux symptom, particularly in patients with severe symptoms. Fexuprazan may offer a therapeutic advantage for patients with severe and persistent nocturnal reflux despite proton pump inhibitor therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Gyeonggi-do, Korea.
- Department of Biostatistics, Dongguk University College of Medicine, Goyang, Gyeonggi-do, Korea.
ORCID-Profile: Yun Jeong Lim
Förderung
- Dongguk University
- Daewoong Pharmaceutical Company
Zitieren
APA
Oh, D. J., Park, D. H., Jung, J., & Lim, Y. J. (2026). Comparison of Fexuprazan and Esomeprazole for the Control of Nocturnal Gastroesophageal Reflux Symptoms: A Randomized, Crossover Study. Journal of Neurogastroenterology and Motility, 32(1), 52-60. https://doi.org/10.5056/jnm25119
Vancouver
Oh DJ, Park DH, Jung J, Lim YJ. Comparison of Fexuprazan and Esomeprazole for the Control of Nocturnal Gastroesophageal Reflux Symptoms: A Randomized, Crossover Study. Journal of Neurogastroenterology and Motility. 2026;32(1):52-60. doi:10.5056/jnm25119
BibTeX
@article{Oh2026,
author = {Oh, Dong Jun and Park, Dong Hwan and Jung, Jiyun and Lim, Yun Jeong},
title = {Comparison of Fexuprazan and Esomeprazole for the Control of Nocturnal Gastroesophageal Reflux Symptoms: A Randomized, Crossover Study},
journal = {Journal of Neurogastroenterology and Motility},
year = {2026},
volume = {32},
number = {1},
pages = {52--60},
doi = {10.5056/jnm25119}
}
EUVIMED